A Phase II, Open-label, Dose Titration, Multi-center Study to Assess the Safety/Tolerability and Efficacy of Osilodrostat in Patients With All Types of Endogenous Cushing's Syndrome Except Cushing's Disease
Phase of Trial: Phase II
Latest Information Update: 14 Feb 2018
At a glance
- Drugs Osilodrostat (Primary)
- Indications Cushing syndrome
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 08 Feb 2018 Planned End Date changed from 31 Oct 2019 to 18 Jul 2018.
- 08 Feb 2018 Planned primary completion date changed from 21 Jun 2019 to 27 Jun 2018.
- 09 Oct 2017 Planned End Date changed from 12 Sep 2019 to 31 Oct 2019.